Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options

Florent Elefteriou, Mateusz Kolanczyk, Aaron Schindeler, David H. Viskochil, Janet M. Hock, Elizabeth K. Schorry, Alvin H. Crawford, Jan M. Friedman, David Little, Juha Peltonen, John C. Carey, David Feldman, Xijie Yu, Linlea Armstrong, Patricia Birch, David L. Kendler, Stefan Mundlos, Feng Chun Yang, Gina Agiostratidou, Kim Hunter-SchaedleDavid A. Stevenson

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

The skeleton is frequently affected in individuals with neurofibromatosis type 1, and some of these bone manifestations can result in significant morbidity. The natural history and pathogenesis of the skeletal abnormalities of this disorder are poorly understood and consequently therapeutic options for these manifestations are currently limited. The Children's Tumor Foundation convened an International Neurofibromatosis Type 1 Bone Abnormalities Consortium to address future directions for clinical trials in skeletal abnormalities associated with this disorder. This report reviews the clinical skeletal manifestations and available preclinical mouse models and summarizes key issues that present barriers to optimal clinical management of skeletal abnormalities in neurofibromatosis type 1. These concepts should help advance optimal clinical management of the skeletal abnormalities in this disease and address major difficulties encountered for the design of clinical trials.

Original languageEnglish
Pages (from-to)2327-2338
Number of pages12
JournalAmerican Journal of Medical Genetics, Part A
Volume149
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Neurofibromatosis 1
Clinical Trials
Bone and Bones
Natural History
Skeleton
Therapeutics
Morbidity
Neoplasms

Keywords

  • Bone
  • Neurofibromatosis
  • NF1
  • Osteoblast
  • Osteoclast
  • Pseudarthrosis
  • Skeletal dysplasia
  • Tibial dysplasia

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Elefteriou, F., Kolanczyk, M., Schindeler, A., Viskochil, D. H., Hock, J. M., Schorry, E. K., ... Stevenson, D. A. (2009). Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options. American Journal of Medical Genetics, Part A, 149(10), 2327-2338. https://doi.org/10.1002/ajmg.a.33045

Skeletal abnormalities in neurofibromatosis type 1 : Approaches to therapeutic options. / Elefteriou, Florent; Kolanczyk, Mateusz; Schindeler, Aaron; Viskochil, David H.; Hock, Janet M.; Schorry, Elizabeth K.; Crawford, Alvin H.; Friedman, Jan M.; Little, David; Peltonen, Juha; Carey, John C.; Feldman, David; Yu, Xijie; Armstrong, Linlea; Birch, Patricia; Kendler, David L.; Mundlos, Stefan; Yang, Feng Chun; Agiostratidou, Gina; Hunter-Schaedle, Kim; Stevenson, David A.

In: American Journal of Medical Genetics, Part A, Vol. 149, No. 10, 10.2009, p. 2327-2338.

Research output: Contribution to journalArticle

Elefteriou, F, Kolanczyk, M, Schindeler, A, Viskochil, DH, Hock, JM, Schorry, EK, Crawford, AH, Friedman, JM, Little, D, Peltonen, J, Carey, JC, Feldman, D, Yu, X, Armstrong, L, Birch, P, Kendler, DL, Mundlos, S, Yang, FC, Agiostratidou, G, Hunter-Schaedle, K & Stevenson, DA 2009, 'Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options', American Journal of Medical Genetics, Part A, vol. 149, no. 10, pp. 2327-2338. https://doi.org/10.1002/ajmg.a.33045
Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK et al. Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options. American Journal of Medical Genetics, Part A. 2009 Oct;149(10):2327-2338. https://doi.org/10.1002/ajmg.a.33045
Elefteriou, Florent ; Kolanczyk, Mateusz ; Schindeler, Aaron ; Viskochil, David H. ; Hock, Janet M. ; Schorry, Elizabeth K. ; Crawford, Alvin H. ; Friedman, Jan M. ; Little, David ; Peltonen, Juha ; Carey, John C. ; Feldman, David ; Yu, Xijie ; Armstrong, Linlea ; Birch, Patricia ; Kendler, David L. ; Mundlos, Stefan ; Yang, Feng Chun ; Agiostratidou, Gina ; Hunter-Schaedle, Kim ; Stevenson, David A. / Skeletal abnormalities in neurofibromatosis type 1 : Approaches to therapeutic options. In: American Journal of Medical Genetics, Part A. 2009 ; Vol. 149, No. 10. pp. 2327-2338.
@article{b116ee1723714132849e05ac91c3f0c4,
title = "Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options",
abstract = "The skeleton is frequently affected in individuals with neurofibromatosis type 1, and some of these bone manifestations can result in significant morbidity. The natural history and pathogenesis of the skeletal abnormalities of this disorder are poorly understood and consequently therapeutic options for these manifestations are currently limited. The Children's Tumor Foundation convened an International Neurofibromatosis Type 1 Bone Abnormalities Consortium to address future directions for clinical trials in skeletal abnormalities associated with this disorder. This report reviews the clinical skeletal manifestations and available preclinical mouse models and summarizes key issues that present barriers to optimal clinical management of skeletal abnormalities in neurofibromatosis type 1. These concepts should help advance optimal clinical management of the skeletal abnormalities in this disease and address major difficulties encountered for the design of clinical trials.",
keywords = "Bone, Neurofibromatosis, NF1, Osteoblast, Osteoclast, Pseudarthrosis, Skeletal dysplasia, Tibial dysplasia",
author = "Florent Elefteriou and Mateusz Kolanczyk and Aaron Schindeler and Viskochil, {David H.} and Hock, {Janet M.} and Schorry, {Elizabeth K.} and Crawford, {Alvin H.} and Friedman, {Jan M.} and David Little and Juha Peltonen and Carey, {John C.} and David Feldman and Xijie Yu and Linlea Armstrong and Patricia Birch and Kendler, {David L.} and Stefan Mundlos and Yang, {Feng Chun} and Gina Agiostratidou and Kim Hunter-Schaedle and Stevenson, {David A.}",
year = "2009",
month = "10",
doi = "10.1002/ajmg.a.33045",
language = "English",
volume = "149",
pages = "2327--2338",
journal = "American Journal of Medical Genetics, Part C: Seminars in Medical Genetics",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Skeletal abnormalities in neurofibromatosis type 1

T2 - Approaches to therapeutic options

AU - Elefteriou, Florent

AU - Kolanczyk, Mateusz

AU - Schindeler, Aaron

AU - Viskochil, David H.

AU - Hock, Janet M.

AU - Schorry, Elizabeth K.

AU - Crawford, Alvin H.

AU - Friedman, Jan M.

AU - Little, David

AU - Peltonen, Juha

AU - Carey, John C.

AU - Feldman, David

AU - Yu, Xijie

AU - Armstrong, Linlea

AU - Birch, Patricia

AU - Kendler, David L.

AU - Mundlos, Stefan

AU - Yang, Feng Chun

AU - Agiostratidou, Gina

AU - Hunter-Schaedle, Kim

AU - Stevenson, David A.

PY - 2009/10

Y1 - 2009/10

N2 - The skeleton is frequently affected in individuals with neurofibromatosis type 1, and some of these bone manifestations can result in significant morbidity. The natural history and pathogenesis of the skeletal abnormalities of this disorder are poorly understood and consequently therapeutic options for these manifestations are currently limited. The Children's Tumor Foundation convened an International Neurofibromatosis Type 1 Bone Abnormalities Consortium to address future directions for clinical trials in skeletal abnormalities associated with this disorder. This report reviews the clinical skeletal manifestations and available preclinical mouse models and summarizes key issues that present barriers to optimal clinical management of skeletal abnormalities in neurofibromatosis type 1. These concepts should help advance optimal clinical management of the skeletal abnormalities in this disease and address major difficulties encountered for the design of clinical trials.

AB - The skeleton is frequently affected in individuals with neurofibromatosis type 1, and some of these bone manifestations can result in significant morbidity. The natural history and pathogenesis of the skeletal abnormalities of this disorder are poorly understood and consequently therapeutic options for these manifestations are currently limited. The Children's Tumor Foundation convened an International Neurofibromatosis Type 1 Bone Abnormalities Consortium to address future directions for clinical trials in skeletal abnormalities associated with this disorder. This report reviews the clinical skeletal manifestations and available preclinical mouse models and summarizes key issues that present barriers to optimal clinical management of skeletal abnormalities in neurofibromatosis type 1. These concepts should help advance optimal clinical management of the skeletal abnormalities in this disease and address major difficulties encountered for the design of clinical trials.

KW - Bone

KW - Neurofibromatosis

KW - NF1

KW - Osteoblast

KW - Osteoclast

KW - Pseudarthrosis

KW - Skeletal dysplasia

KW - Tibial dysplasia

UR - http://www.scopus.com/inward/record.url?scp=70349498475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349498475&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.33045

DO - 10.1002/ajmg.a.33045

M3 - Article

C2 - 19764036

AN - SCOPUS:70349498475

VL - 149

SP - 2327

EP - 2338

JO - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

JF - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

SN - 1552-4825

IS - 10

ER -